Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
EnzymeRx. LLC
EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase
June 10th, 2008
EnzymeRx, a clinical stage biotechnology company, announced it has raised $14 million from funds managed by Pequot Capital Management and has acquired worldwide rights, excluding Taiwan, to uricase-PEG 20 from Polaris Pharmaceuticals, which will also hold an equity stake in EnzymeRx. Uricase-PEG 20 is a pegylated form of the enzyme uricase (urate oxidase) that has previously completed a single dose phase I trial and is being developed for the treatment of refractory gout and tumor lysis syndrome. Plans for additional clinical studies, including a multi-dose phase II study in refractory gout patients, are under way. EnzymeRx's President and Chief Executive Officer Tony...
Source: Cancer Weekly (2008-06-10)
|
